Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials.
Autor: | Rabiee Rad M; School of Medicine, Isfahan University of Medical Science, Hezarjarib Ave, Isfahan, 81746-73461, Iran., Ghasempour Dabaghi G; School of Medicine, Isfahan University of Medical Science, Hezarjarib Ave, Isfahan, 81746-73461, Iran. ghasempoorghazal@gmail.com., Habibi D; Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Science, Isfahan, Iran. |
---|---|
Jazyk: | angličtina |
Zdroj: | The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology [Egypt Heart J] 2023 Jan 12; Vol. 75 (1), pp. 4. Date of Electronic Publication: 2023 Jan 12. |
DOI: | 10.1186/s43044-023-00328-7 |
Abstrakt: | Background: Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients. Main Body: A total number of 539 patients were enrolled in four randomized clinical trials. The mean age of patients was 57.9 years and was followed for 29.3 weeks. Pooled analysis showed a significant improvement in clinical response (Log OR = 0.65; p = 0.01) and the number of patients with a reduction of ≥ 1 NYHA function class (Log OR = 0.64, p = 0.00). It was found that mavacamten did not significantly affect the Kansas City Cardiomyopathy Questionnaire (KCCQ) (SMD = 0.43, p = 0.08), peak oxygen uptake (PVO Conclusions: Mavacamten proved to be effective and well-tolerated for the treatment of HCM. Mavacamten improved the signs and symptoms of HOCM and decreased EF in these patients without serious adverse events in the clinical trials. (© 2023. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |